The decision – first reported by Stat citing Biogen’s head of corporate development, Adam Keeney – is not an exit from the digital health category, but an acknowledgement that Biogen will ...

are joining Cerevel’s board alongside Bain Capital managing directors Adam Koppel and Chris Gordon. The most advanced assets in the portfolio are a D1 partial agonist expected to start phase III ...

Biogen Pharmachem Industries Ltd share price was down by -7.48% from the previous closing price of ₹1.07. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Akebia Therapeutics (market cap: $421.09 million) reported its Q4 2024 earnings, revealing a net loss and revenue decline compared to the previous year. The company’s earnings per share (EPS) came in ...

Archer founder and CEO, Adam Goldstein, echoed the sentiment, highlighting the role of AI and software as pivotal in shaping the future of aviation. The announcement comes at a time when the aviation ...

Pharmacies are not precluded from assisting and educating their patients. The Medicare prescription drug benefit is extremely complex, and many patients need the guidance of their pharmacists.

Credit: sasirin pamai / Shutterstock. US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND trial to assess felzartamab in adult kidney transplant recipients with late ...